Navigation Links
PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
Date:12/17/2007

- Company Initiates Phase1b/2 Clinical Trial in Breast Cancer -

SAN ANTONIO and SOUTH PLAINFIELD, N.J., Dec. 17 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms announced the presentation of preclinical and Phase 1 data regarding PTC299, its novel, internally discovered, vascular endothelial growth factor (VEGF) inhibitor. PTC299 is an orally bioavailable investigational drug which is designed to inhibit the production of VEGF in tumors, acting upstream of current anti-angiogenic agents that function at the site of the VEGF receptor. The preclinical and clinical data presented today formed the basis for the recent initiation of a Phase 1b/2 clinical trial of PTC299 in patients with advanced breast cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

"We are pleased to present these preclinical data on PTC299, which show drug activity in multiple preclinical models of human cancer, including breast cancer," said Langdon Miller, M.D., Chief Medical Officer of PTC Therapeutics, Inc. "Based on the safety profile and pharmacokinetic results from our Phase 1a studies, we are excited to have initiated a Phase 1b/2 trial of PTC299 in patients with advanced breast cancer. Our hope is that PTC299 will offer an active, well-tolerated, and convenient oral therapy for patients with breast cancer and other tumor types."

The data were detailed in a poster presentation at the San Antonio Breast Cancer Symposium entitled, "Preclinical Efficacy in Breast Cancer Xenografts and Phase 1 Results of PTC299, a Novel VEGF Expression Inhibitor," (Poster Number 6082).

In the preclinical studies, PTC299 was administered to mice harboring established human breast tumor xenografts. In these studies,
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2008)...e-USNewswire/ -- Abnormalities in auditory and lan... autism spectrum disorder by using magnetoencephal...y at the annual meeting of the Radiological Societ...we can record the tiny magnetic fields associated ...rts, Ph.D., vice chair of research in the Departme...
(Date:11/28/2008)...ewswire-FirstCall/ -- Eli Lilly and Company,(NYSE...Application (sNDA) from,the U.S. Food and Drug Ad...),for the management of chronic pain. Lilly plans... 2009, adding data from a recently completed posit...nee. , The decision does not affect duloxet...
(Date:11/26/2008)... Children whose eyes are... increased risk of developing mental illness by ea...inic study published this month in Pediatrics , th...atrics. , , The retrospective study examine...mus (misaligned eyes) and compared them with recor...
(Date:11/26/2008)...ects , , FRANKLIN, Mass., Nov. 26 /PRNewswi...ard: PLCSF) announced today that it has received f...ation (FDA) for its U.S. pivotal trial to study th...(TM) and associated therapy in the prevention of ... FDA also approved PLC,s request to expand their i...
Breaking Medicine Technology:Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Eye Divergence in Children Triples Risk of Mental Illness 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Possible biological explanation for C Section linked allergies and asthma found 19976 1Possible biological explanation for C Section linked allergies and asthma found 19976 2Crdentia Announces 2008 First Quarter Results 19972 1Crdentia Announces 2008 First Quarter Results 19972 2Crdentia Announces 2008 First Quarter Results 19972 3Crdentia Announces 2008 First Quarter Results 19972 4Crdentia Announces 2008 First Quarter Results 19972 5Crdentia Announces 2008 First Quarter Results 19972 6Crdentia Announces 2008 First Quarter Results 19972 7FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 1FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 2FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 3FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 4Iraq war service 3A A risk factor for bronchiolitis 3F 19967 1Iraq war service 3A A risk factor for bronchiolitis 3F 19967 2
..., FL -- (MARKET WIRE) -- July 06, 2007 -- DOR BioP...://studio.financialcontent.com/Engine?Account=iwir...p://studio.financialcontent.com/Engine?Account=iwi...R" or the "Company") announced today that the Euro...7 B1, with claims related to,oral vaccination usin...
...ublished in The Lancet on TMC125, an Investigation... /PRNewswire/ -- Data from two,ongoing Phase 3 stu... HIV-1 adult patients with documented non-nucleosi...tease inhibitor (PI),resistance reached an undetec...ndetectable level < 50 HIV-1 RNA copies/mL) with,T...
Other Medicine Technology:DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 6TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4
(Date:12/1/2008)... 1 This December, Anthem Blue,Cro...he Anthem Blue Cross,HealthFair Bus travels the s...,on Monday, December 1 from the Anthem offices in ...n a multi-city tour to include Los Angeles, Ventur...isco (see detailed schedule,below). , (Pho...
(Date:12/1/2008)...PRNewswire/ -- Question. What would happen if,we ...lding exercise? The,fitness world would certainly...rship fees would have to close. 2. Phony exercise ...t. 3. We would never have to spend another dime on...,s take-home pay is now estimated at 35 billion,d...
(Date:12/1/2008)...D Global Telemedicine, Inc. deploys telemedicine d...t program. 17 school sites in Sevier County, Tenne..., North Chelmsford, MA (PR...dicine & Cherokee Health Systems collaborated ...s in Sevier County, Tennessee. In addition to thi...
(Date:12/1/2008)...stage breast cancer who have undergone breast augm...l-breast radiation treatment called brachytherapy,...l meeting of the Radiological Society of North Ame...ave better cosmetic outcomes and avoid the risk of...ndergo whole-breast radiation therapy. , "We are...
Breaking Medicine News(10 mins):Health News:Anthem Blue Cross Gives the Gift of Health to California 2Health News:Anthem Blue Cross Gives the Gift of Health to California 3Health News:Push-Ups: 'It's Horizontal Jogging' 2Health News:Telemedicine Becoming More Relevant to Children's Health Within School Systems. 2Health News:Telemedicine Becoming More Relevant to Children's Health Within School Systems. 3Health News:Breast cancer treatment offers better outcome to women with implants 2
...2006 issue of General Dentistry, the AGD’s clinica...especially that of the tongue is harmful and shoul...e, the report describes the condition of a young g...was massive scar tissue formation around the area ...
... milk substitute, and a highly vulnerable commodit...ealth concerns determine what goes into formula mi.../ The Codex Alimentarius Commission, part of bot...of the United Nations and the World Health Organis...
...ched a $38 million project along with major region...u threat in Asia and the Pacific. // The Manila-b...e resources urgently needed to help control and re...us, and to increase the region's preparedness for ...
...ons (ASPS) reports say that plastic surgery was pe... The ethnic community opts for this surgery than ...nce their appearance or minimize the signs of agin...nd more people opted for it in the year 2005 with ...
Other Medicine News:
15" overall length, 9" handle.
Gimmi Yasargil Aneurysm-Vessel-Clips
Yasargil Phynox Aneurysm Clips Standard
EDM Ventricular Drainage Kit, with Drip Chamber with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in
Medicine Products: